PlainPharmaWatch

CMS Open Payments · Program Year 2024

Granata Bio Corporation

Granata Bio Corporation reported $5,493.03 across General Payments, Research, and Ownership to 22 physicians and teaching hospitals across 22 transactions.

See the rankings → How this is sourced
$5.5K
All-tracks total
22
Transactions
22
Recipients
#1703
of 1,925 companies

Granata Bio Corporation reported $5,493.03 across all CMS Open Payments tracks (General + Research + Ownership) to 22 physicians and teaching hospitals in Program Year 2024 - ranking #1703 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $5,493.03, averaging $249.68 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer granata-bio-corporation Granata Bio Corporation

$5.5K · #1703/1,925 · 0.0% industry · PY2024

  • TOT $5.5K
  • RANK #1703
  • SHARE 0.0%
  • TXN 22
  • RCP 22
  • CAT 3
  • GEN $5.5K
  • TOP1 54.6%
  • PY 2024

Volume peers

Nearest volume peer: Aquestive Therapeutics, Inc. ($5.5K)

Bridge to Life Ltd$5.6KRare Disease Therapeutics, I…$5.6KKarl Storz Endovision, Inc.$5.5KGranata Bio Corporation (thi…$5.5KAquestive Therapeutics, Inc.$5.5K
All-tracks payment totals near Granata Bio Corporation (CMS Open Payments PY2024)

Granata Bio Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Granata Bio Corporation

$5,493.03: that is what Granata Bio Corporation reported in payments to 22 physicians and teaching hospitals during Program Year 2024, spread across 22 transactions ($249.68 per transaction, $249.68 per recipient). The company sits at rank #1703 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Consulting Fee" leads the 3-category general-payment breakdown below at $3.0K (54.6% of General Payments, 1 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

"Consulting Fee" leads Granata Bio Corporation's 3-category general-payment breakdown at $3.0K, 54.6% of the reported total.

How Granata Bio Corporation divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$3.0K2. Food and Beverage$1.4K3. Travel and Lodging$1.1K
Payment Type Amount Transactions
Consulting Fee $3.0K 1
Food and Beverage $1.4K 19
Travel and Lodging $1.1K 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $4,522.19 (82.3%) of $5,493.03 in this company's General Payments records across 19 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Granata Bio Corporation

The five named recipients with the highest reported General Payments from this company

Pietro Bortoletto$3.0KKarina Stroker$1.1KPeter Lindner$153.64Ariel Dunn$153.64Alexandra Poch$102.98
  1. 1

    Pietro Bortoletto

    $3,000.00 across 1 reported transactions

  2. 2

    Karina Stroker

    $1,111.93 across 2 reported transactions

  3. 3

    Peter Lindner

    $153.64 across 2 reported transactions

  4. 4

    Ariel Dunn

    $153.64 across 2 reported transactions

  5. 5

    Alexandra Poch

    $102.98 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Granata Bio Corporation's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Granata Bio Corporation.

Collegium Pharmaceutical, Inc.

HHI 3442

American Rheumatology Network, LLC

HHI 3431

Bristol Myers Squibb Company

HHI 3447

Biocircuit Technologies Inc

HHI 3424

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Granata Bio Corporation.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Granata Bio Corporation's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.